0.3241
price down icon5.16%   -0.0148
 
loading
Aditxt Inc stock is traded at $0.3241, with a volume of 201.71K. It is down -5.16% in the last 24 hours and down -70.51% over the past month. Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.
See More
Previous Close:
$0.3389
Open:
$0.3385
24h Volume:
201.71K
Relative Volume:
0.08
Market Cap:
$2.94M
Revenue:
$749.50K
Net Income/Loss:
$-29.60M
P/E Ratio:
-0.000862
EPS:
-376.0263
Net Cash Flow:
$-22.09M
1W Performance:
-7.78%
1M Performance:
-70.51%
6M Performance:
-99.61%
1Y Performance:
-99.77%
1-Day Range:
Value
$0.32
$0.3388
1-Week Range:
Value
$0.31
$0.3789
52-Week Range:
Value
$0.31
$380.00

Aditxt Inc Stock (ADTX) Company Profile

Name
Name
Aditxt Inc
Name
Phone
909-488-0844
Name
Address
737 N. FIFTH STREET, SUITE 200, RICHMOND
Name
Employee
47
Name
Twitter
Name
Next Earnings Date
2024-12-18
Name
Latest SEC Filings
Name
ADTX's Discussions on Twitter

Compare ADTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
ADTX 0.3241 2.94M 749.50K -29.60M -22.09M -376.03
VRTX 447.00 115.74B 10.63B -479.80M -1.35B 13.33
REGN 742.11 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 588.93 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.68 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.55 24.49B 3.30B -501.07M 1.03B 11.54

Aditxt Inc Stock (ADTX) Latest News

pulisher
Nov 20, 2024

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 - Marketscreener.com

Nov 20, 2024
pulisher
Nov 19, 2024

Aditxt extends merger agreement end date to January 2025 By Investing.com - Investing.com UK

Nov 19, 2024
pulisher
Nov 19, 2024

Appili Therapeutics Moves Forward with Aditxt Acquisition - TipRanks

Nov 19, 2024
pulisher
Nov 19, 2024

Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc. - The Manila Times

Nov 19, 2024
pulisher
Nov 18, 2024

Aditxt Inc. (ADTX) Quarterly 10-Q Report - Quartz

Nov 18, 2024
pulisher
Nov 18, 2024

Aditxt, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 18, 2024
pulisher
Nov 18, 2024

ADTX stock plunges to 52-week low of $0.32 amid market challenges - Investing.com Canada

Nov 18, 2024
pulisher
Nov 14, 2024

Evofem Cuts Q3 Operating Loss 31%, Acquires SOLOSEC Rights Despite Sales Dip | ADTX Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 14, 2024

Enviri Corp (NYSE: NVRI): Blank Check On Growth? - Stocks Register

Nov 14, 2024
pulisher
Nov 14, 2024

Appili Therapeutics shareholders vote in favor of Aditxt transaction - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025 - The Manila Times

Nov 14, 2024
pulisher
Nov 13, 2024

Aditxt, Inc. (NASDAQ:ADTX) Short Interest Update - Defense World

Nov 13, 2024
pulisher
Nov 08, 2024

Aditxt suspends equity financing amid acquisition strategy - Investing.com

Nov 08, 2024
pulisher
Nov 08, 2024

Aditxt suspends equity financing amid acquisition strategy By Investing.com - Investing.com UK

Nov 08, 2024
pulisher
Nov 07, 2024

ADTX stock plunges to 52-week low, touches $0.42 - Investing.com India

Nov 07, 2024
pulisher
Nov 07, 2024

ADTX stock plunges to 52-week low, touches $0.42 By Investing.com - Investing.com UK

Nov 07, 2024
pulisher
Nov 07, 2024

Aditxt Secures Overwhelming Shareholder Approval for Appili Therapeutics Acquisition | ADTX Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 06, 2024

Appili Shareholders Approve Acquisition by Aditxt - TipRanks

Nov 06, 2024
pulisher
Nov 06, 2024

Appili Therapeutics Announces Results of Special Meeting of Shareholders - Financial Post

Nov 06, 2024
pulisher
Nov 06, 2024

Appili Therapeutics Announces Results of Special Meeting of Shareholders - GlobeNewswire Inc.

Nov 06, 2024
pulisher
Nov 06, 2024

Aditxt announces Evofem secures voting agreements with investors for merger - TipRanks

Nov 06, 2024
pulisher
Nov 06, 2024

Evofem Biosciences Gains Support for Aditxt Merger - TipRanks

Nov 06, 2024
pulisher
Nov 06, 2024

Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem - Quantisnow

Nov 06, 2024
pulisher
Nov 06, 2024

Evofem Secures Investor Support for Proposed Merger through Voting Agreements - StreetInsider.com

Nov 06, 2024
pulisher
Nov 06, 2024

Evofem Secures Key Merger Support as Aditxt Completes $5M Investment Commitment | ADTX Stock News - StockTitan

Nov 06, 2024
pulisher
Nov 06, 2024

Aditxt Discloses Information About Compliance with Nasdaq Listing Requirements in 8-K Filing** - Defense World

Nov 06, 2024
pulisher
Nov 05, 2024

Aditxt, Inc. Focuses on Growth Amid Nasdaq Compliance - TipRanks

Nov 05, 2024
pulisher
Nov 02, 2024

A Biotech Empire Rises in Inland Southern California - Site Selection Magazine

Nov 02, 2024
pulisher
Nov 01, 2024

Aditxt receives positive FDA feedback on ATI-1801 development By Investing.com - Investing.com Australia

Nov 01, 2024
pulisher
Nov 01, 2024

ADTXAditxt, Inc. Latest Stock News & Market Updates - StockTitan

Nov 01, 2024
pulisher
Nov 01, 2024

Aditxt receives positive FDA feedback on ATI-1801 development - Investing.com India

Nov 01, 2024
pulisher
Oct 31, 2024

Evofem Biosciences enters agreements amid merger plans - Investing.com

Oct 31, 2024
pulisher
Oct 31, 2024

Evofem Biosciences Faces Merger and Credit Challenges - TipRanks

Oct 31, 2024
pulisher
Oct 31, 2024

Evofem Biosciences enters agreements amid merger plans By Investing.com - Investing.com UK

Oct 31, 2024
pulisher
Oct 31, 2024

ADTX stock plunges to 52-week low of $0.53 amid market challenges - Investing.com

Oct 31, 2024
pulisher
Oct 31, 2024

Aditxt’s Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission - StockTitan

Oct 31, 2024
pulisher
Oct 31, 2024

Appili Therapeutics’ FDA Alignment and Aditxt Acquisition - TipRanks

Oct 31, 2024
pulisher
Oct 31, 2024

Appili Therapeutics announces FDA alignment on ATI-1801 NDA requirements - TipRanks

Oct 31, 2024
pulisher
Oct 31, 2024

Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission - The Manila Times

Oct 31, 2024
pulisher
Oct 30, 2024

Aditxt Enters Major Investment Agreement with Evofem - TipRanks

Oct 30, 2024
pulisher
Oct 30, 2024

Aditxt appoints Sylvia Hermina to board By Investing.com - Investing.com Canada

Oct 30, 2024
pulisher
Oct 29, 2024

Sylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership with Broader Perspectives - Quantisnow

Oct 29, 2024
pulisher
Oct 29, 2024

Aditxt appoints Sylvia Hermina to board - Investing.com

Oct 29, 2024
pulisher
Oct 29, 2024

Aditxt, Inc. Appoints Sylvia Hermina to its Board of Directors - Marketscreener.com

Oct 29, 2024
pulisher
Oct 29, 2024

Evofem Biosciences, Inc. announced that it has received $2.28 million in funding from Aditxt, Inc. - Marketscreener.com

Oct 29, 2024
pulisher
Oct 28, 2024

Is Aditxt Inc (NASDAQ: ADTX) Doomed From The Get-Go? - Stocks Register

Oct 28, 2024
pulisher
Oct 28, 2024

Evofem Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits - Quantisnow

Oct 28, 2024
pulisher
Oct 28, 2024

Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem - Quantisnow

Oct 28, 2024
pulisher
Oct 24, 2024

ADTX stock touches 52-week low at $0.89 amid sharp decline - Investing.com UK

Oct 24, 2024
pulisher
Oct 21, 2024

Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time - StockTitan

Oct 21, 2024
pulisher
Oct 17, 2024

Aditxt shares sold by major stakeholder HRT Financial for $29,874 - Investing.com South Africa

Oct 17, 2024

Aditxt Inc Stock (ADTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Aditxt Inc Stock (ADTX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
HRT FINANCIAL LP
10% Owner
Oct 16 '24
Sale
1.17
25,534
29,875
0
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):